Preventing p38 MAPK-mediated MafA degradation ameliorates β-cell dysfunction under oxidative stress.

Area of Science:

• Endocrinology
• Molecular Biology
• Diabetes Research

Background:

• Reduced MafA expression is linked to beta-cell dysfunction in type 2 diabetes.
• Oxidative stress exacerbates MafA reduction, contributing to diabetic conditions.
• p38 MAPK is identified as a key regulator of MafA degradation under oxidative stress.

Purpose of the Study:

• To elucidate the mechanisms of MafA degradation under oxidative stress.
• To investigate whether preventing MafA degradation can ameliorate beta-cell dysfunction.
• To explore potential therapeutic strategies for diabetes targeting MafA stability.

Main Methods:

• Investigated p38 MAPK binding and phosphorylation of MafA.
• Utilized mutant MafA (T134A, T57A) to assess degradation pathways.
• Examined the role of proteasomal activator PA28γ in MafA regulation.
• Assessed glucose-stimulated insulin secretion in response to interventions.

Main Results:

• p38 MAPK directly binds and degrades MafA via the ubiquitin-proteasomal pathway.
• Oxidative stress-induced MafA degradation is dependent on p38 MAPK phosphorylation at T134.
• Expression of T134A-MafA preserved glucose-stimulated insulin secretion under oxidative stress.
• PA28γ expression, which targets GSK3-phosphorylated MafA, is reduced under oxidative stress.

Conclusions:

• Identified distinct p38 MAPK-dependent pathways for MafA degradation under oxidative and nonoxidative conditions.
• Inhibiting MafA degradation under oxidative stress shows potential for treating beta-cell dysfunction.
• Targeting MafA stability offers a novel therapeutic avenue for diabetes management.